AU2011265228A1 - Methods of mitigating effects of radiation and reducing the risk of systemic infection - Google Patents

Methods of mitigating effects of radiation and reducing the risk of systemic infection Download PDF

Info

Publication number
AU2011265228A1
AU2011265228A1 AU2011265228A AU2011265228A AU2011265228A1 AU 2011265228 A1 AU2011265228 A1 AU 2011265228A1 AU 2011265228 A AU2011265228 A AU 2011265228A AU 2011265228 A AU2011265228 A AU 2011265228A AU 2011265228 A1 AU2011265228 A1 AU 2011265228A1
Authority
AU
Australia
Prior art keywords
gly
asp
ala
subject
thrombin peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011265228A
Other languages
English (en)
Inventor
Darrell Carney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of AU2011265228A1 publication Critical patent/AU2011265228A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
AU2011265228A 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection Abandoned AU2011265228A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35406710P 2010-06-11 2010-06-11
US61/354,067 2010-06-11
PCT/US2011/040006 WO2011156729A2 (en) 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection

Publications (1)

Publication Number Publication Date
AU2011265228A1 true AU2011265228A1 (en) 2013-05-23

Family

ID=44533067

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011265228A Abandoned AU2011265228A1 (en) 2010-06-11 2011-06-10 Methods of mitigating effects of radiation and reducing the risk of systemic infection

Country Status (5)

Country Link
EP (1) EP2579891A2 (https=)
JP (1) JP2013529600A (https=)
AU (1) AU2011265228A1 (https=)
CA (1) CA2802176A1 (https=)
WO (1) WO2011156729A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021207411A1 (en) * 2020-04-07 2021-10-14 Chrysalis Biotherapeutics Tp508 acute therapy for patients with respiratory virus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
EP1539214A4 (en) 2002-07-02 2008-01-02 Orthologic Corp Thrombin
AU2003247848B2 (en) 2002-07-02 2006-12-21 The Board Of Regents, The University Of Texas System Thrombin peptide derivative dimers
US7294596B2 (en) 2005-03-14 2007-11-13 Diamorph Ceramic Ab Sintered ceramic material with improved properties and method for its manufacturing
CN101563102B (zh) * 2006-09-22 2014-12-17 德克萨斯系统大学董事会 治疗内皮功能障碍的方法
EP2155234A1 (en) * 2007-04-10 2010-02-24 The Board of Regents,The University of Texas System Combination therapy for chronic dermal ulcers

Also Published As

Publication number Publication date
EP2579891A2 (en) 2013-04-17
CA2802176A1 (en) 2011-12-15
JP2013529600A (ja) 2013-07-22
WO2011156729A3 (en) 2012-05-10
WO2011156729A2 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
EP2875826B1 (en) Composition for preventing or treating sepsis
US10350261B2 (en) Extracellular histones as biomarkers for prognosis and molecular targets for therapy
JP4307561B2 (ja) 創傷の治癒
AU2014346051B2 (en) Use of IL-22 dimers in manufacture of medicaments for treating pancreatitis
CN102482323B (zh) 新型肽及其应用
CN105358704A (zh) Ptd-smad7治疗剂
CA2709027A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
ZA200603396B (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
ES2251953T3 (es) Uso de desmopresina en la preparacion de un medicamento inhibidor de la diseminacion metastasica durante la cirugia del cancer.
US20130101574A1 (en) Methods of using thrombin peptide derivatives
AU2011265228A1 (en) Methods of mitigating effects of radiation and reducing the risk of systemic infection
US8133491B1 (en) Compositions and methods for treatment of hyperplastic disorders
EP2687224A1 (en) Medicament for wound treatment
CN107787325B (zh) 新型肽及其应用
NZ541493A (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
US8895502B2 (en) β2-glycoprotein I peptide inhibitors
US10646553B2 (en) Use of recombinant human calcineurin B subunit
CN104961831A (zh) 一种修饰的重组人内皮抑素及其应用
US10028906B2 (en) Method and kit for treating a solid tumor and associated desmoplasia
RU2008125169A (ru) Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента грелин и его производные или вещество, воздействующее на рецептор ghs-r1а
CN120939206A (zh) Metrnl蛋白与氯吡格雷联合治疗血栓的药物组合物及其应用
RU2008125167A (ru) Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента дезацил-грелин и его производные
CN118451094A (zh) 抗病毒肽及其使用方法
TW201622741A (zh) 狗圍肛腺瘤之治療方法
WO2019231860A1 (en) Method for treating or preventing radiotherapy- and chemotherapy-associated oral mucositis using locally administered heparin binding epidermal growth factor like growth factor (hb-egf)

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 11 APR 2013 .

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application